Yingxin Feng

In the vastness of the ocean lie many unique organisms, genes and molecules. They offer huge potential for new medicines to fight disease but the pipeline for their development is nascent. Most drugs on the market originate from terrestrial sources. But the companies working to derive drugs from marine animals and plants were paying attention in January, when an agreement to manage biodiversity in waters beyond national jurisdiction came into effect: the high seas treaty.

China’s Fisheries Law, which determines how those working in the sector can make a living, is being revised. The latest draft was published by the Standing Committee of the National People’s Congress last month while a public consultation process was also completed. The revisions are intended to bolster protections for fishery resources and so promote high-quality development in the sector.

Corresponding Author Yingxin Feng Department of Physics and Competence Centre for Catalysis, Chalmers University of Technology, SE-412, 96 Göteborg, Sweden Search for more papers by this author